APA (7th ed.) Citation

MA, M., CE, W., J, L., M, C., S, G., AM, D., . . . JC, D. (2025). Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: Results from a 96-week open-label extension study. The European respiratory journal, 66(1), . https://doi.org/10.1183/13993003.02435-2024

Chicago Style (17th ed.) Citation

MA, Mall, et al. "Elexacaftor/tezacaftor/ivacaftor in Children Aged ≥6 years with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: Results from a 96-week Open-label Extension Study." The European Respiratory Journal 66, no. 1 (2025). https://doi.org/10.1183/13993003.02435-2024.

MLA (9th ed.) Citation

MA, Mall, et al. "Elexacaftor/tezacaftor/ivacaftor in Children Aged ≥6 years with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: Results from a 96-week Open-label Extension Study." The European Respiratory Journal, vol. 66, no. 1, 2025, https://doi.org/10.1183/13993003.02435-2024.